Intranasal erythropoietin therapy in nervous system disorders
- PMID: 21143002
- DOI: 10.1517/17425247.2011.540236
Intranasal erythropoietin therapy in nervous system disorders
Abstract
Importance of the field: Erythropoietin (EPO) is a growth hormone and cytokine that plays an important role in erythropoiesis and neuroprotection. However, EPO treatment for neurological diseases requires repeated injections or high-dose systemic administration, which may cause systemic side effects. The lack of any effective treatment of acute and chronic neurodegenerative diseases and the promising outcome by EPO in animal models in vivo demand a critical evaluation of intranasal EPO delivery to the brain as an alternative administration method.
Areas covered in this review: The current use and intranasal administration of EPO and its derivatives in preclinical studies and recent clinical trials with EPO in neurological diseases.
What the reader will gain: This paper gives an overview of the therapeutic considerations of intranasal EPO and EPO derivatives for neuroprotection.
Take home message: Intranasal delivery (ID) of neuroprotective drugs is an area of great interest. Among the administration strategies used at present, ID of EPO is the most promising. Further preclinical and clinical studies are needed to evaluate the potential significance of this alternative route for increasing EPO bioavailability and decreasing side effects.
Similar articles
-
Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.Drug Metabol Drug Interact. 2011;26(2):65-9. doi: 10.1515/DMDI.2011.007. Epub 2011 Jul 14. Drug Metabol Drug Interact. 2011. PMID: 21756166 Review.
-
Erythropoietin in stroke: quo vadis.Expert Opin Biol Ther. 2010 Jun;10(6):937-49. doi: 10.1517/14712598.2010.481435. Expert Opin Biol Ther. 2010. PMID: 20394473 Review.
-
Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection.Expert Opin Drug Deliv. 2008 Dec;5(12):1313-21. doi: 10.1517/17425240802544159. Expert Opin Drug Deliv. 2008. PMID: 19040394 Review.
-
Neuroprotective role of erythropoietin in neonates.J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:105-7. doi: 10.3109/14767058.2012.715025. J Matern Fetal Neonatal Med. 2012. PMID: 22958035 Review.
-
Erythropoietin and the nervous system.Brain Res. 2004 Mar 12;1000(1-2):19-31. doi: 10.1016/j.brainres.2003.12.037. Brain Res. 2004. PMID: 15053948 Review.
Cited by
-
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.BMC Neurol. 2017 Jul 4;17(1):129. doi: 10.1186/s12883-017-0908-0. BMC Neurol. 2017. PMID: 28676085 Free PMC article. Clinical Trial.
-
Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?Front Neurosci. 2019 Apr 24;13:386. doi: 10.3389/fnins.2019.00386. eCollection 2019. Front Neurosci. 2019. PMID: 31105516 Free PMC article. Review.
-
Intranasal administration of erythropoietin rescues the photoreceptors in degenerative retina: a noninvasive method to deliver drugs to the eye.Drug Deliv. 2019 Dec;26(1):78-88. doi: 10.1080/10717544.2018.1556361. Drug Deliv. 2019. PMID: 30744451 Free PMC article.
-
Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.Psychopharmacology (Berl). 2012 Feb;219(3):687-98. doi: 10.1007/s00213-011-2511-1. Epub 2011 Sep 23. Psychopharmacology (Berl). 2012. PMID: 21947319 Review.
-
Effects of erythropoietin and methylprednisolone on AQP4 expression in astrocytes.Mol Med Rep. 2017 Nov;16(5):5924-5930. doi: 10.3892/mmr.2017.7330. Epub 2017 Aug 22. Mol Med Rep. 2017. PMID: 28849166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
